anonymous
Guest
anonymous
Guest
Biogen slashes Aduhelm price in half, foreshadows significant layoffs as sales continue to stagnate – Endpoints News
https://endpts.com/biogen-slashes-a...ficant-layoffs-as-sales-continue-to-stagnate/
Biogen slashes Aduhelm price in half, foreshadows significant layoffs as sales continue to stagnate
Jason Mast
Editor
In a surprise move, Biogen announced Monday that it will cut the price of its controversial Alzheimer’s drug Aduhelm in half, slashing the cost from $56,000 to $28,000.
The sudden discount marks a sudden turnaround for the big biotech as it struggles to turn around a drug whose stuck-in-the-mud sales and political ramifications have sent the company into turmoil and triggered the ousting of its longtime chief scientist. Biogen’s leadership had resisted calls since June to reduce the price of the drug.
The company also acknowledged the inner crisis for the first time in Friday’s statement, announcing that it will institute “cost-reduction measures” to reach $500 million in annualized savings. Biogen did not release details but STAT has reported the restructuring plan calls for more than 1,000 layoffs in 2022, the largest round of layoffs in the company’s 43-year history.
https://endpts.com/biogen-slashes-a...ficant-layoffs-as-sales-continue-to-stagnate/
Biogen slashes Aduhelm price in half, foreshadows significant layoffs as sales continue to stagnate
Jason Mast
Editor
In a surprise move, Biogen announced Monday that it will cut the price of its controversial Alzheimer’s drug Aduhelm in half, slashing the cost from $56,000 to $28,000.
The sudden discount marks a sudden turnaround for the big biotech as it struggles to turn around a drug whose stuck-in-the-mud sales and political ramifications have sent the company into turmoil and triggered the ousting of its longtime chief scientist. Biogen’s leadership had resisted calls since June to reduce the price of the drug.
The company also acknowledged the inner crisis for the first time in Friday’s statement, announcing that it will institute “cost-reduction measures” to reach $500 million in annualized savings. Biogen did not release details but STAT has reported the restructuring plan calls for more than 1,000 layoffs in 2022, the largest round of layoffs in the company’s 43-year history.